Cassava Sciences Inc vs Mondaycom Ltd — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Mondaycom Ltd trades at $88.38 (market cap $3.76B). The key difference: Mondaycom Ltd is far larger — about 95.4× Cassava Sciences Inc's market cap, and Mondaycom Ltd is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Mondaycom Ltd for 16 Days on average.
| FLNA | MNDY | |
|---|---|---|
Market Cap | $39.40M | $3.76B |
Volume | 759,018 | 836,200 |
Sector | Health | Technology |
52-Week High | $4.64 | $205.24 |
52-Week Low | $0.68 | $58.81 |
Typical Hold Time | 37 Days | 16 Days |
Enterprise Value | -$43.28M | $2.92B |
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Monday.com (MNDY) is trading at $89.50, up 7.17% with strong momentum following consecutive earnings beats. The stock shows bullish technical signals with support at $86 and resistance at $90. Fundamentally, the company maintains robust revenue growth ($1.23B in 2025) and high gross margins (88.74%), though valuation multiples remain elevated with P/E at 37.69. Recent news highlights strong enterprise client growth and AI integration initiatives at the upcoming Elevate '26 conference.
The outlook remains positive with 65% analyst buy ratings and a $108.64 consensus target, representing 21% upside. Key risks include competitive pressure from Meta's enterprise push and elevated valuation sensitivity. Earnings momentum and enterprise expansion provide catalysts, but investors should monitor Q3 2026 results against the $1.37 EPS expectation for sustained growth validation.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →